QSAR models for cxcr2 receptor antagonists based on the genetic algorithm for data preprocessing prior to application of the pls linear regression method and design of the new compounds using in silico virtual screening

Molecules

Volumn 16, Issue 3, 2011, Pages 1928-1955

  Asadollahi, Tahereh ^a   Dadfarnia, Shayessteh ^a   Shabani, Ali Mohammad Haji ^a   Ghasemi, Jahan B ^b   Sarkhosh, Maryam ^a  

^a YAZD UNIVERSITY   (Iran)

^b K N TOOSI UNIVERSITY OF TECHNOLOGY   (Iran)

Author keywords

CXCR2 receptor; Estimation of pIC50; In silico screening; QSAR

Indexed keywords

CHEMOKINE RECEPTOR CXCR2;

ALGORITHM; ARTICLE; CHEMICAL MODEL; DRUG ANTAGONISM; DRUG DESIGN; IC 50; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REGRESSION ANALYSIS; STATISTICAL MODEL;

ALGORITHMS; DRUG DESIGN; INHIBITORY CONCENTRATION 50; LEAST-SQUARES ANALYSIS; LINEAR MODELS; MODELS, CHEMICAL; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, INTERLEUKIN-8B;

EID: 79953100083     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules16031928     Document Type: Article

References (50)

1. Holmes, W.E.; Lee, J.; Kuang, W.J.; Rice, G.C.; Wood, W.I. Structure and functional expression of a human interleukin-8 receptor. Science 1991, 253, 1278-1280. (Pubitemid 21917277)
2. Murphy, P.M.; Tiffany, H.L. Cloning of complementary DNA encoding a functional human interleukin-8 receptor. Science 1991, 253, 1280-1283. (Pubitemid 21917278)
3. Murphy, P.M.; Baggiolini, M.; Charo, I.F.; Hebert, C.A.; Horuk, R.; Matsushima, K.; Miller, L.H.; Oppenheim, J.J.; Power, C.A. International Union of Pharmacology. XXII. Nomenclature for Chemokine Receptors. Pharmacol. Rev. 2000, 52, 145-176. (Pubitemid 30127598)
4. Loetscher, P.; Seitz, M.; Clark-Lewis, I.; Baggiolini, M.; Moser, B. Both interleukin-8 receptors independently mediate chemotaxis: Jurkat cells transfected with IL-8R1 or IL-8R2 migrate in response to IL-8, GROa and NAP-2. FEBS Lett. 1994, 341, 187-192. (Pubitemid 24102679)
5. Ahuja, S.K.; Lee, J.C.;Murphy, P.M. The CXC chemokines growth-regulated oncogene (GRO) a, GROβ, GROγ, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human Interleukin-8 Receptor. J. Biol. Chem. 1996, 271, 20545-20550. (Pubitemid 26281830)
6. Bizzarri, C.; Allegretti, M.; Bitondo, R. Di; Cervellera, M. N.; Collota, F.; Bertini, R. Pharmacological inhibition of Interleukin-8 (CXCL8) as a new approach for the prevention and treatment of several human diseases. Curr. Med. Chem. Anti-inflamm. Anti-Allergy Agents 2003, 2, 67-79.
7. Busch-Petersen, J. Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases. Curr. Med. Chem. 2006, 6, 1345-1352. (Pubitemid 44144920)
8. Ribeiro, F.A.L.; Ferreira, M.M.C. QSPR models of boiling point, octanol-water partition coefficient and retention time index of polycyclic aromatic hydrocarbons. J. Mol. Struct. Theochem. 2003, 663, 109-126.
9. Molfetta, F.A.; Bruni, A.T.; Rosseli, F.P.; Silva, A.B.F. A partial least squares and principal component regression study of quinone compounds with trypanocidal activity. Struct. Chem. 2007, 18, 49-57. (Pubitemid 46202924)
10. Tong, W.; Hong, H.; Xie, Q.; Shi, L.; Fang, H.; Perkins, R. Assessing QSAR limitations-A regulatory perspective. Curr. Comput. Aided Drug Des. 2005, 1, 195-205.
11. He, L.; Jurs, P.C. Assessing the reliability of a QSAR model's predictions. J. Mol. Graphics Model. 2005, 23, 503-523. (Pubitemid 40803520)
12. Ghafourian, T.; Cronin, M.T.D. The impact of variable selection on the modelling of oestrogenicity. SAR QSAR Environ. Res. 2005, 16, 171-190. (Pubitemid 40623248)
13. Tropsha, A.; Gramatica, P.; Gombar,V.K. The importance of being earnest: Validation is the absolute essential for successful application and interpretation of QSPR models. QSAR Comb. Sci. 2003, 22, 69-77. (Pubitemid 36717473)
14. Shahlaei, M.; Fassihi, A.; Saghaie, L. Application of PC-ANN and PC-LS-SVM in QSAR of CCR1 antagonist compounds: A comparative study. Eur. J. Med. Chem. 2010, 45, 1572-1582.
15. Aher, Y.D.; Agrawal, A.; Bharatam, P.V.; Garg, P. 3D-QSAR studies of substituted 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas as CCR5 receptor antagonists. J. Mol. Model. 2007, 13, 519-529. (Pubitemid 46404035)
16. Afantitis, A.; Melagraki, G.; Sarimveis, H.; Koutentis, P.A.; Markopoulosd, J.; Igglessi- Markopoulou, O. Investigation of substituent effect of 1-(3,3-diphenylpropyl)-piperidinyl phenylacetamides on CCR5 binding affinity using QSAR and virtual screening techniques. J. Comput. Aided Mol. Des. 2006, 20, 83-95. (Pubitemid 43899119)
17. Afantitis, A.; Melagraki, G.; Sarimveis, H.; Igglessi-Markopoulou, O.; Kollias, G. A novel QSAR model for predicting the inhibition of CXCR3 receptor by 4-N-aryl-[1,4] diazepane ureas. Eur. J. Med. Chem. 2009, 44, 877-884.
18. Bhonsle, J.B.; Wang, Z.X.; Tamamura, H.; Fujii, N.; Peiper, S.C.; Trent, J.O. A simple, automated Quasi-4D-QSAR, Quasi-multi way PLS approach to develop highly predictive QSAR models for highly flexible CXCR4 inhibitor cyclic pentapeptide ligands using scripted common molecular modeling tools. QSAR Comb. Sci. 2005, 24, 620-630. (Pubitemid 41074330)
19. Khelebnikov, A.I.; Schepetkin, I.A.; Quinn, M.T. Quantitative structure activity relationships for small non- peptide antagonistsof CXCR2: Indirect 3D approach using the frontal polygon method. Bioorg. Med. Chem. Lett. 2006, 14, 352-365. (Pubitemid 41767595)
20. Ghasemi, J.B.; Zohrabi, P.; Khajehsharifi, H. Quantitative structure-activity relationship study of nonpeptide antagonists of CXCR2 using stepwise multiple linear regression analysis. Monatsh. Chem. 2010, 141, 111-118.
21. Yu, Y.; Dwyer, M.P.; Chao, J.; Aki, C.; Chao, J.; Purakkattle, B.; Rindgen, D.; Bond, R.; Mayer- Ezel, R.; kway, J.; et al. Synthesis and structure-activity relationships of heteroaryl substituted- 3,4-diamino-3- cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists. Bioorg. Med. Chem. Lett. 2008, 18, 1318-1322. (Pubitemid 351226544)
22. Winters, M.P.; Crysler, C.; Subasinghe, N.; Ryan, D.; Leong, L.; Zhao, S.; Donatelli, R.; Yurkow, E.; Mazzulla, M.; Boczon, L.; et al. Carboxylic acid bioisosteres acylsulfonamides, acylsulfamides, and sulfonylureas as novel antagonists of the CXCR2 receptor. Bioorg. Med. Chem. Lett. 2008, 18, 1926-1930. (Pubitemid 351380887)
23. Walters, I.; Austin, C.; Austin, R.; Bonnert, R.; Cage, P.; Christie, M.; Ebden, M.; Gardiner, S.; Grahames, C.; Hill, S.; et al. Evaluation of a series of bicyclic CXCR2 antagonists. Bioorg. Med. Chem. Lett. 2008, 18, 798-803.
24. Kennard, R.W.; Stone, L.A. Computer aided design of experiments. Technometrics 1969, 11, 137-148.
25. Melagraki, G.; Afantitis, A.; Makridima, K.; Sarimveis, H.; Igglessi-Markopoulou, O. Prediction of toxicity using a novel RBF neural network training methodology. J. Mol. Model. 2006, 12, 297-305. (Pubitemid 43337199)
26. Wu, W.; Walczak, B.; Massart, D.L.; Heuerding, S.; Erni, F.; Last, I.R.; Prebble, K.A.; Artificial neural networks in classification of NIR spectral data: Design of the training set. Chemometr. Intell. Lab. Syst. 1996, 33, 35-46. (Pubitemid 26168648)
27. Ghosh, P.; Ghosh, M.; Bagchi, M.C. On an aspect of calculated molecular descriptors in QSAR studies of quinolone antibacterials. Mol. Divers. 2006, 10, 415-427. (Pubitemid 46156696)
28. Chakraborti, A.K.; Gopalakrishnan, B.; Sobhia, M.E.; Malde, A. 3D-QSAR studies of indole derivatives as phosphodiesterase IV inhibitors. Eur. J. Med. Chem. 2003, 38, 975-982. (Pubitemid 37452424)
29. Agrawal, V.K.; Sohgaura, R.; Khadikar, P.V.; QSAR studies on biological activity of piritrexim analogues against pc DHFR. Bioorg. Med. Chem. 2002, 10, 2919-2926. (Pubitemid 34761870)
30. Todeschini, R.; Milano Chemometrics, QSPR Group, http://michem.disat. unimib.it/chm/.
31. Todeschini, R.; Consonni, V. Handbook of Molecular Descriptors; Wiely-VCH: Weinheim, Germany, 2000.
32. Wold, S.; Eriksson, L. In Chemometric Methods in Molecular Design; van de Waterbeemd, H., Ed.; VCH: Weinheim, Germany, 1995; pp. 312-317.
33. Golbraikh, A.; Tropsha, A. Beware of q2! J. Mol. Graph. Model. 2002, 20, 269-276.
34. Leardi, R.; Boggia, R.; Terrile, M. Genetic algorithms as a strategy for feature selection. J. Chemometr. 1992, 6, 267-281.
35. Jalali, H.M.; Konuze, E. Use of quantitative structure property relationships in predicting the Kraft point of anionic surfactants. Int. Electron. J. Mol. Des. 2002, 1, 410-417.
36. Acevedo-Martínez, J.; Escalona-Arranz, J.C.; Villar-Rojas, A.; Téllez-Palmero, F.; Pérez-Rosés, R.; González L.; Carrasco-Velar, R. Quantitative study of the structure-retention index relationship in the imine family. J. Chromatogr. A 2006, 1102, 238-244. (Pubitemid 41790354)
37. Hou, T.J.; Wang, J.M.; Liao, N.; Xu, X.J. Application of Genetic algorithms on the structureactivity relationship analysis of some cinnamaides. J. Chem. Inf. Comput. Sci. 1999, 39, 775-781.
38. Hasegawa, K. GA strategy for variable selection in QSAR studies: Application of GA-Based region selection to a 3D-QSAR study of acetylcholinesterase inhibitors. J. Chem. Inf. Comput. Sci. 1999, 39, 112-120. (Pubitemid 129676566)
39. Goicoechea, H.C.; Olivieri, A.C. Wavelength selection for multivariate calibration using a genetic algorithm: A novel initialization strategy. J. Chem. Inf. Comput. Sci. 2001, 42, 1146-1153. (Pubitemid 35360298)
40. van de Waterbeemd, H. Chemometric Methods in Molecular Design, Methods and Principles in Medicinal Chemistry; Verlag Chemie: Weinheim, Germany, 1995; Volume 2.
41. Rogers, D.; Hopfinger, A.J. Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships. J. Chem. Inf. Comput. Sci. 1994, 34, 854-866.
42. Hasegawa, K.; Kimura, T.; Funatsu, K. GA strategy for variable selection in QSAR studies: Enhancement of comparative molecular binding energy analysis by GA-based PLS method. Quant. Struct. Act. Relat. 1999, 18, 262-272. (Pubitemid 29364073)
43. Sagradoa, S.; Cronin, M.T.D. Application of the modelling power approach to variable subset selection for GA-PLS QSAR models. Anal. Chim. Acta 2008, 609, 169-174.
44. Tropsha, A.; Golbraikh, A. Predictive QSAR modeling workflow model applicability domains and virtual screening. Curr. Pharm. Des. 2007, 13, 3494-3504. (Pubitemid 350238939)
45. Muegge, I.; Oloff, S. Advances in virtual screening. Drug Discov. Today Technol. 2006, 3, 405-411. (Pubitemid 46164322)
46. Melagraki, G.; Afantitis, A.; Sarimveis, H.; Koutentis, P.A.; Markopoulos, J.; Igglessi- Markopoulou, O. Optimization of biaryl piperidine and 4-amino-2-biarylurea MCH1 receptor antagonists using QSAR modeling, classification techniques and virtual screening. J. Comput. Aided Mol. Des. 2007, 21, 251-267. (Pubitemid 46630053)
47. Melagraki, G.; Afantitis, A.; Sarimveis, H.; Koutentis, P. A.; Kollias, G. A.; Igglessi- Markopoulou, O. Predictive QSAR workflow for the in silico identification and screening of novel HDAC inhibitors. Mol. Divers. 2009, 13, 301-311.
48. Eriksson, L.; Jaworska, J.; Worth, A.P.; Cronin, M.T.D.; McDowell, R.M. Methods for reliability and uncertainty assessment and for applicability evaluations of classification- and regressionbased QSARs. Environ. Health Perspect. 2003, 111, 1361-1375. (Pubitemid 37021142)
49. Gramatica, P. Principles of QSAR models validation: Internal and external. QSAR Comb. Sci. 2007, 26, 694-701. (Pubitemid 46932857)
50. Jaworska, J.S.; Nikolova, J.N.; Aldenberg, T. QSAR applicability domain estimation by projection of the training set in descriptor space: A review. ATLA Altern. Lab. Anim. 2005, 33, 445-459. (Pubitemid 41613738)